ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2026
Molecular epidemiology of carbapenemase-carrying Klebsiella pneumoniae in China: Distribution of carbapenemase types, capsular serotypes, and virulence factors.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a large-scale genomic analysis of 9,082 carbapenemase-producing Klebsiella pneumoniae (CPKP) isolates originating from China and collected between 2005 and 2024, using genomes retrieved from the NCBI database. The aim was to characterize population structure, resistance determinants, capsular diversity, and virulence-associated loci at a national scale. The CPKP population exhibited substantial genetic diversity, encompassing 233 sequence types (STs), 109 capsular serotypes (KLs), and a wide range of carbapenemase genes. KPC-2-producing ST11 was the dominant epidemic lineage nationwide and remained prevalent throughout the study period. Within ST11, a temporal shift in capsular serotypes was observed, with KL47 predominating during 2013–2015 and KL64 becoming dominant from 2016 onward, while both serotypes persisted at substantial frequencies. In contrast, metallo-β-lactamases such as NDM-1, NDM-5, and IMP-4 showed heterogeneous clonal distributions without a single dominant lineage. Carbapenem-producing isolates belonging to hypervirulence-associated capsular serotypes (KL1 and KL2) were detected sporadically. KL1-type CPKP isolates were predominantly associated with ST23 and carried multiple classical virulence-associated loci, whereas KL2-type CPKP isolates were distributed across diverse STs and exhibited more variable virulence gene carriage. Carbapenemase-producing KL1 and KL2 isolates were first detected in this dataset in 2013 in different regions of China. Virulence gene distribution was strongly structured by capsular serotype and clonal background. Classical hypervirulence-associated loci, including aerobactin, salmochelin, colibactin, and regulators of the mucoid phenotype (rmpADC), were largely confined to KL1 and a subset of KL2 lineages and were infrequently detected among the major carbapenem-producing clones, ST11 and ST15. In contrast, yersiniabactin was widespread among CPKP isolates but showed lineage-specific associations with distinct ICEKp elements. Resistance-associated plasmid backbones, including ColRNAI, IncFIB/IncHI1B, and IncFII, were commonly detected. Overall, this study provides a comprehensive population-level overview of CPKP in China and highlights the expansion of highly resistant clones alongside a limited and structured distribution of classical hypervirulence determinants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.